(MedPage Today) — Drugmaker Sarepta Therapeutics said it would resume shipping its gene therapy for some patients, following a brief pause requested by regulators.
The FDA said it recommended lifting the hold for young patients with Duchenne…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/116714
Author :
Publish date : 2025-07-29 14:40:00
Copyright for syndicated content belongs to the linked Source.
